LakeShore Biopharma Advances PIKA Rabies Vaccine Approval
Company Announcements

LakeShore Biopharma Advances PIKA Rabies Vaccine Approval

LakeShore Biopharma (LSB) has released an update.

LakeShore Biopharma has submitted a Biologics License Application to the Drug Regulatory Authority of Pakistan for its PIKA rabies vaccine, which promises faster immune response and could significantly reduce the rabies burden in high-prevalence countries like Pakistan. The vaccine’s accelerated one-week regimen has shown promising results in trials, potentially making rabies vaccines more accessible and effective. This advancement underscores LakeShore’s commitment to addressing global health challenges through innovative biotechnology.

For further insights into LSB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyLakeShore Biopharma initiates BLA submission to DRAP for PIKA rabies vaccine
TipRanks Auto-Generated NewsdeskLakeShore Biopharma Announces Leadership Transition
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App